<p>Zentalis Pharmaceuticals, Inc.（納斯達克代碼：ZNTL - 獲取免費報告）在覆蓋該公司的九家券商中獲得了 “持有” 的共識評級，Marketbeat.com 報道。五位股票研究分析師對該股票給予了持有推薦，四位則給予了買入推薦。在過去一年中，覆蓋該股票的券商的平均 12 個月目標價為 8.24 美元。</p>
<p>一些股票分析師最近對 ZNTL 股票發表了評論。Wedbush 在 5 月 15 日的報告中重申了 “中性” 評級，並對 Zentalis Pharmaceuticals 的股票設定了 4.00 美元的目標價。HC Wainwright 在 5 月 15 日的報告中重申了 “買入” 評級，並設定了 10.00 美元的目標價。</p>
<p><strong>查看我們最新的 ZNTL 股票分析</strong></p>
<h2>Zentalis Pharmaceuticals 價格表現</h2>
<p>Zentalis Pharmaceuticals 的股票在週二開盤價為 1.51 美元。該股票的 50 日移動平均線為 1.33 美元，200 日移動平均線為 2.00 美元。該公司的市值為 1.0865 億美元，市盈率為-0.61，貝塔值為 1.61。Zentalis Pharmaceuticals 的 12 個月低點為 1.01 美元，12 個月高點為 8.87 美元。</p>
<p>Zentalis Pharmaceuticals（納斯達克代碼：ZNTL - 獲取免費報告）最近於 5 月 14 日發佈了季度財報。該公司報告季度每股收益（EPS）為-0.67 美元，符合分析師的共識預期（-0.67 美元）。研究分析師預計 Zentalis Pharmaceuticals 在當前年度將發佈-2.42 美元的每股收益。</p>
<h2>內部人士下注</h2>
<p>在其他 Zentalis Pharmaceuticals 的新聞中，董事 Scott Dunseth Myers 在 4 月 30 日的交易中購買了 21,000 股該公司的股票。這些股票的平均購買成本為每股 1.40 美元，總交易額為 29,400.00 美元。收購後，該董事現在直接擁有 281,192 股該公司的股票，價值 393,668.80 美元。這筆交易代表了他們持股比例的 8.07% 的增加。該交易已在證券交易委員會的備案中披露，您可以通過此鏈接訪問。公司內部人士持有 1.90% 的股票。</p>
<h2>機構投資者對 Zentalis Pharmaceuticals 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近買賣了 ZNTL 的股票。Savant Capital LLC 在第四季度購買了 Zentalis Pharmaceuticals 的新股份，價值約 72,000 美元。Ieq Capital LLC 在第四季度獲得了 Zentalis Pharmaceuticals 的新頭寸，價值約 46,000 美元。Anfield Capital Management LLC 在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 100.0%。Anfield Capital Management LLC 現在擁有 129,318 股該公司的股票，價值 392,000 美元，此前在上個季度又收購了 64,659 股。Charles Schwab Investment Management Inc.在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 22.4%。Charles Schwab Investment Management Inc.現在擁有 497,362 股該公司的股票，價值 1,507,000 美元，此前在上個季度又收購了 91,152 股。最後，Raymond James Financial Inc.在第四季度獲得了 Zentalis Pharmaceuticals 的新頭寸，價值約 68,000 美元。</p>
<h2>關於 Zentalis Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Zentalis Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於發現和開發小分子治療藥物，用於治療各種癌症。其產品候選藥物包括 ZN-c3，一種 WEE1 抑制劑，針對晚期實體腫瘤和血液惡性腫瘤的治療；作為單藥治療子宮漿液性癌症的二期臨牀試驗；在 Cyclin E1 驅動的高等級漿液性卵巢癌、輸卵管癌或原發性腹膜癌的二期臨牀試驗；與 PARPi 聯合用於鉑耐藥卵巢癌的 1/2 期臨牀試驗；與化療聯合用於鉑耐藥卵巢癌、腹膜癌或輸卵管癌的 1b 期臨牀試驗；與化療聯合用於復發或難治性骨肉瘤的 1/2 期臨牀試驗；與 encorafenib 和 cetuximab 聯合用於突變轉移性結直腸癌的 1/2 期臨牀試驗；以及與化療聯合用於胰腺癌的 1/2 期臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Zentalis Pharmaceuticals</li>
<li>賣空 - 利弊分析</li>
<li>新催化劑將推動 NVIDIA 的股價更高</li>
<li>如何利用高貝塔股票最大化投資收益</li>
<li>中國市場動向：MCHI、PDD、BIDU 顯示看漲趨勢</li>
<li>什麼是成長股及其投資方式</li>
<li>Palantir 抵禦空頭，領跑 2025 年標準普爾 500 指數</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Zentalis Pharmaceuticals 嗎？</h2>
<p>在考慮 Zentalis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意之前立即購買……而 Zentalis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Zentalis Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ZNTL

<p>Zentalis Pharmaceuticals, Inc.（納斯達克代碼：ZNTL）獲得了九家券商的共識評級為 “持有”，其中五位分析師建議持有，四位建議買入。12 個月的平均目標價格為 8.24 美元。該股票開盤價為 1.51 美元，12 個月的最低價為 1.01 美元，最高價為 8.87 美元。最近，董事 Scott Dunseth Myers 以每股 1.40 美元購買了 21,000 股。機構投資者也表現活躍，多家機構在該公司增持了新股份</p>

<p>Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given a consensus rating of &#34;Hold&#34; by the nine brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.24.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.（納斯達克代碼：ZNTL - 獲取免費報告）在覆蓋該公司的九家券商中獲得了 “持有” 的共識評級，Marketbeat.com 報道。五位股票研究分析師對該股票給予了持有推薦，四位則給予了買入推薦。在過去一年中，覆蓋該股票的券商的平均 12 個月目標價為 8.24 美元。</p>
</div><p>A number of equities analysts have recently commented on ZNTL shares. Wedbush restated a &#34;neutral&#34; rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reiterated a &#34;buy&#34; rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th.</p>
<div class="lb-trans"><p>一些股票分析師最近對 ZNTL 股票發表了評論。Wedbush 在 5 月 15 日的報告中重申了 “中性” 評級，並對 Zentalis Pharmaceuticals 的股票設定了 4.00 美元的目標價。HC Wainwright 在 5 月 15 日的報告中重申了 “買入” 評級，並設定了 10.00 美元的目標價。</p>
</div><p><strong>View Our Latest Stock Analysis on ZNTL</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 ZNTL 股票分析</strong></p>
</div><h2>Zentalis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 價格表現</h2>
</div><p>Zentalis Pharmaceuticals stock opened at $1.51 on Tuesday. The stock's 50-day moving average is $1.33 and its 200-day moving average is $2.00. The company has a market cap of $108.65 million, a price-to-earnings ratio of -0.61 and a beta of 1.61. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $8.87.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals 的股票在週二開盤價為 1.51 美元。該股票的 50 日移動平均線為 1.33 美元，200 日移動平均線為 2.00 美元。該公司的市值為 1.0865 億美元，市盈率為-0.61，貝塔值為 1.61。Zentalis Pharmaceuticals 的 12 個月低點為 1.01 美元，12 個月高點為 8.87 美元。</p>
</div><p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). Research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals（納斯達克代碼：ZNTL - 獲取免費報告）最近於 5 月 14 日發佈了季度財報。該公司報告季度每股收益（EPS）為-0.67 美元，符合分析師的共識預期（-0.67 美元）。研究分析師預計 Zentalis Pharmaceuticals 在當前年度將發佈-2.42 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Zentalis Pharmaceuticals 的新聞中，董事 Scott Dunseth Myers 在 4 月 30 日的交易中購買了 21,000 股該公司的股票。這些股票的平均購買成本為每股 1.40 美元，總交易額為 29,400.00 美元。收購後，該董事現在直接擁有 281,192 股該公司的股票，價值 393,668.80 美元。這筆交易代表了他們持股比例的 8.07% 的增加。該交易已在證券交易委員會的備案中披露，您可以通過此鏈接訪問。公司內部人士持有 1.90% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Zentalis Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000. Ieq Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $46,000. Anfield Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company's stock worth $392,000 after acquiring an additional 64,659 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $68,000.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買賣了 ZNTL 的股票。Savant Capital LLC 在第四季度購買了 Zentalis Pharmaceuticals 的新股份，價值約 72,000 美元。Ieq Capital LLC 在第四季度獲得了 Zentalis Pharmaceuticals 的新頭寸，價值約 46,000 美元。Anfield Capital Management LLC 在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 100.0%。Anfield Capital Management LLC 現在擁有 129,318 股該公司的股票，價值 392,000 美元，此前在上個季度又收購了 64,659 股。Charles Schwab Investment Management Inc.在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 22.4%。Charles Schwab Investment Management Inc.現在擁有 497,362 股該公司的股票，價值 1,507,000 美元，此前在上個季度又收購了 91,152 股。最後，Raymond James Financial Inc.在第四季度獲得了 Zentalis Pharmaceuticals 的新頭寸，價值約 68,000 美元。</p>
</div><h2>About Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Zentalis Pharmaceuticals</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於發現和開發小分子治療藥物，用於治療各種癌症。其產品候選藥物包括 ZN-c3，一種 WEE1 抑制劑，針對晚期實體腫瘤和血液惡性腫瘤的治療；作為單藥治療子宮漿液性癌症的二期臨牀試驗；在 Cyclin E1 驅動的高等級漿液性卵巢癌、輸卵管癌或原發性腹膜癌的二期臨牀試驗；與 PARPi 聯合用於鉑耐藥卵巢癌的 1/2 期臨牀試驗；與化療聯合用於鉑耐藥卵巢癌、腹膜癌或輸卵管癌的 1b 期臨牀試驗；與化療聯合用於復發或難治性骨肉瘤的 1/2 期臨牀試驗；與 encorafenib 和 cetuximab 聯合用於突變轉移性結直腸癌的 1/2 期臨牀試驗；以及與化療聯合用於胰腺癌的 1/2 期臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Zentalis Pharmaceuticals</li>
<li>Short Selling - The Pros and Cons</li>
<li>New Catalysts to Drive NVIDIA’s Stock Price Even Higher</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>China Market Movers: MCHI, PDD, BIDU Show Bullish Trends</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Palantir Defies Bears, Leads S&amp;P 500 in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Zentalis Pharmaceuticals</li>
<li>賣空 - 利弊分析</li>
<li>新催化劑將推動 NVIDIA 的股價更高</li>
<li>如何利用高貝塔股票最大化投資收益</li>
<li>中國市場動向：MCHI、PDD、BIDU 顯示看漲趨勢</li>
<li>什麼是成長股及其投資方式</li>
<li>Palantir 抵禦空頭，領跑 2025 年標準普爾 500 指數</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ZNTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Zentalis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Zentalis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Zentalis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Zentalis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意之前立即購買……而 Zentalis Pharmaceuticals 並不在名單上。</p>
</div><p>While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Zentalis Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ZeZentalis Pharma（納斯達克股票代碼：ZNTL）被券商給予平均評級為 “持有”